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ABSTRACT: Advancements toward an improved vaccine
against Bacillus anthracis, the causative agent of anthrax, have
focused on formulations composed of the protective antigen
(PA) adsorbed to aluminum hydroxide. However, due to the
labile nature of PA, antigen stability is a primary concern for
vaccine development. Thus, there is a need for a delivery
system capable of preserving the immunogenicity of PA
through all the steps of vaccine fabrication, storage, and
administration. In this work, we demonstrate that biodegrad-
able amphiphilic polyanhydride nanoparticles, which have
previously been shown to provide controlled antigen delivery, antigen stability, immune modulation, and protection in a
single dose against a pathogenic challenge, can stabilize and release functional PA. These nanoparticles demonstrated polymer
hydrophobicity-dependent preservation of the biological function of PA upon encapsulation, storage (over extended times and
elevated temperatures), and release. Specifically, fabrication of amphiphilic polyanhydride nanoparticles composed of 1,6-bis(p-
carboxyphenoxy)hexane and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane best preserved PA functionality. These studies
demonstrate the versatility and superiority of amphiphilic nanoparticles as vaccine delivery vehicles suitable for long-term storage.
KEYWORDS: protective antigen for anthrax, protein stability, polyanhydrides, nanoparticles
■ INTRODUCTION
Anthrax is a significant public health concern due to its
potential as a bioterrorism and biowarfare agent. Use of the
currently licensed alum-adjuvanted anthrax vaccine adsorbed
(AVA) poses many concerns due to its high reactogenicity,
multidose (five) immunization schedule followed by yearly
boosters, and painful side effects.1 The recombinant protective
antigen (PA) from Bacillus anthracis, the key element of the
AVA vaccine that confers immunity against an anthrax
infection, has been the focus for new vaccines.2 PA is the
receptor-binding subunit for both lethal factor (LF) and edema
factor (EF), which, upon binding, lead to the formation of
lethal toxin (LT) and edema toxin (ET), respectively.3
Although highly immunogenic, PA is unfortunately a labile
recombinant protein, especially in low pH and high temper-
ature environments.4−7 These stability concerns have led to
manufacturing roadblocks during a phase I clinical trial for a
new anthrax vaccine based on PA.8
In addition to stability concerns during the vaccine
manufacturing process, there are other obstacles for PA-based
vaccines. PA circulating in the bloodstream is eliminated within
six hours;3,9 this limited in vivo half-life may fail to induce a
protective immune response. Studies by Zinkernagel and others
have shown that antigen persistence is a key element associated
with the development of a protective immune response.10,11
Several methods have been employed to increase PA availability
to the immune system and improve its immunogenicity,
including engineering recombinant PA, incorporating other
antigens or adjuvants in the vaccine, evaluating alternate
delivery routes, and using controlled delivery systems.3
Currently, the AVA vaccine is administered intramuscularly,
and many murine studies have focused on subcutaneous
delivery of PA. As an alternative, intranasal vaccination has been
reported as the best route for induction of a protective immune
response.3,12 While PA is a relatively good immunogen, it may
be essential to use an adjuvant; however, well-known mucosal
adjuvants (e.g., cholera, pertussis, and edema toxins and CpG
DNA) have limitations due to their potential toxicity when
delivered by this route in humans.3,13
This work focuses on the development and refinement of a
controlled delivery system for PA based on biodegradable
polyanhydride nanoparticles. Polyanhydrides are a class of
biomaterials with excellent biocompatibility and have been
extensively studied as vaccine delivery vehicles and adju-
vants.14−19 These polymer formulations provide safe parenteral
delivery,20 enhanced adjuvanticity,16,17,21 sustained release of
encapsulated antigens,22−28 and a stabilizing environment for
protein antigens during fabrication, storage, and re-
lease.22−26,28−30 Specifically, micro- and nanoparticles made
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of copolymers based upon sebacic anhydride (SA), 1,6-bis(p-
carboxyphenoxy)hexane (CPH), and 1,8-bis(p-carboxyphe-
noxy)-3,6-dioxaoctane (CPTEG) are suitable for inhalation or
injection. Moreover, they possess tunable antigen release
kinetics22−28,30 that provide an in vivo antigen depot, thereby
allowing for sustained antigen exposure and eliminating the
need for multiple administrations. These surface eroding
polymers slowly release encapsulated antigen, minimizing
exposure to unfavorable aqueous environments.
The overall goal of this work was to design nanoparticle-
based formulations capable of encapsulating and releasing
biologically functional PA that results in a robust, high avidity,
neutralizing antibody response after a single administration. In
this regard, nanoparticles based on 50:50 CPTEG:CPH, 20:80
CPTEG:CPH, 50:50 CPH:SA, and 20:80 CPH:SA were
investigated for their ability to stabilize and release biologically
active and immunogenic PA. In contrast to CPH:SA nano-
particles, amphiphilic CPTEG:CPH nanoparticles better
preserved the functionality and immunogenicity of PA during
nanoparticle fabrication, storage, and release. The use of
amphiphilic polyanhydride nanoparticles as delivery vehicles
presents a viable solution for long-term vaccine storage.
■ EXPERIMENTAL SECTION
Materials. Chemicals needed for polymerization, nano-
particle fabrication, and buffer preparation included acetic
anhydride, chloroform, methylene chloride, petroleum ether,
pentane, monobasic potassium phosphate, and dibasic
potassium phosphate; all were purchased from Fisher Scientific
(Fairlawn, NJ). Monomer synthesis utilized the following
chemicals: 1,6-dibromohexane, triethylene glycol, 4-hydrox-
ybenzoic acid, and 1-methyl-2-pyrrolidinone; these were
purchased from Sigma Aldrich (St. Louis, MO); 4-p-
fluorobenzonitrile was purchased from Apollo Scientific
(Cheshire, U.K.); and sulfuric acid, acetonitrile, dimethyl
formamide, toluene, and potassium carbonate were obtained
from Fisher Scientific. Deuterated chemicals for NMR (nuclear
magnetic resonance) analysis, chloroform and dimethyl
sulfoxide were purchased from Cambridge Isotope Laboratories
(Andover, MA).
Polymer Synthesis, Nanoparticle Fabrication, Protein
Encapsulation, and Characterization. The CPH and
CPTEG monomers were synthesized as described previ-
ously.31,32 The SA monomer was purchased from Sigma
Aldrich (St. Louis, MO). Prepolymer and polymers were
synthesized as described before.28,33 The CPTEG:CPH and
CPH:SA copolymers were formed into nanoparticles as
described previously.17,27,29 Briefly, PA (NIH Biodefense and
Emerging Infections Research Resources Repository, Manassas,
VA) loaded nanoparticles (2% (w/w)) were fabricated by
dissolving the desired polymer in methylene chloride at a
concentration of 25 mg/mL. The desired amount of lyophilized
PA was added to the dissolved polymer, and the solution was
sonicated (40 Hz for 30 s), poured into a nonsolvent (pentane)
at a solvent to nonsolvent ratio of 1 to 200, and then vacuum
filtered to recover the PA-loaded nanoparticles (20−150 mg
batch size). Polymer molecular mass, chemical structure, and
chemical composition were determined with 1H NMR
spectroscopy using a Varian VXR 300 MHz spectrometer
(Varian Inc., Palo Alto, CA). Specifically, the molecular mass
was determined by end group analysis of NMR spectra.
Nanoparticle size and morphology were characterized with
scanning electron microscopy (SEM; JEOL 840 A, JEOL
Peabody, MA).
In Vitro Protein Release Kinetics. PA-loaded nano-
particles at a concentration of approximately 50 mg/mL were
incubated with 0.1 M PBS buffer (pH 7.4) in capped
microcentrifuge tubes. Samples were sonicated to ensure
uniform nanoparticle distribution and placed in a shaker/
incubator at 37 °C. Sample supernatants were removed (entire
volume) incrementally to measure the amount of released PA
(PArel), which was analyzed using a microbicinchoninic acid
(BCA) assay. Once supernatants were removed, equivalent
volumes of PBS buffer were added back to maintain perfect
sink conditions. Data is presented as cumulative percentage of
PA released, which was determined by normalizing the
cumulative amount released at each time point by the total
amount encapsulated into the nanoparticles.22−28,30
In Vitro pH Change upon Nanoparticle Degradation.
Blank nanoparticles at a concentration of approximately 100
mg/mL were incubated with 0.1 M PBS buffer (pH 7.6) in
microcentrifuge tubes. Samples were sonicated to ensure
uniform nanoparticle distribution and placed in a shaker/
incubator at 37 °C. The pH measurements were carried out at
various time points with a pH probe to monitor the buildup of
acidic degradation products.
In Vitro Release of PA for Analysis of Bioactivity,
Antigenicity, and Structure. Treatment groups tested for
their effect on PA stability were 20:80 CPTEG:CPH, 50:50
CPTEG:CPH, 20:80 CPH:SA, and 50:50 CPH:SA nano-
particles, native PA (i.e., positive control stored at −20 °C),
and protein exposed to nanoparticle fabrication conditions
(NFC) which included sonication (40 Hz for 30 s), solvent
exposure (methylene chloride and pentane), and vacuum
drying. All groups were sonicated and incubated with 0.1 M
PBS buffer (pH 7.4) in microcentrifuge tubes in a shaker/
incubator at 37 °C. In order to accumulate enough of the PArel
for characterization, PA-loaded nanoparticles were incubated
for two days. Following release, supernatants were removed and
the concentration, antigenicity, bioactivity, and structural
alterations of the PArel were assessed.
Circular Dichroism: Secondary Structure. Far UV
circular dichroism (CD) (190−250 nm) was used to study
the changes in protein secondary structure of the PArel. All CD
spectra were collected for samples on a Jasco J-170
spectropolarimeter (Easton, MD). The emission spectrum
from 200 to 260 nm was analyzed for shifts in molar ellipticity
and wavelength, which are indicative of alterations in protein
secondary structure. The experiments were performed in
triplicate using a 200 μL sample volume.
Fluorescence Spectroscopy: Tertiary Structure. Fluo-
rescence spectroscopy was used to study the changes in tertiary
structure of the PArel with a Cary Eclipse fluorescence
spectrometer (Varian, Inc., Palo Alto, CA). Samples were
excited at a wavelength of 280 nm and a voltage of 800 V,
which resulted in an emission spectrum that corresponds to the
tryptophan and tyrosine residues of the protein. The emission
spectrum from 300 to 500 nm was analyzed for shifts in peak
intensity and wavelength that are indicative of alterations in
protein tertiary structure. The experiments were performed in
triplicate.
In Vitro Release of PA for in Vivo Administration of
the PArel. PA-loaded nanoparticle (2% w/w) samples (200
mg) were incubated in 0.1 M PBS (pH 7.4) for 14 days at 4 °C
in dialysis cassettes (4,000 Da MWCO) to accumulate enough
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of the PArel for immunization. This release was carried out at 4
°C to prevent temperature induced instability. Protein
concentration was determined with a micro-BCA assay, and
all samples were adjusted to a final concentration of 200 μg/
mL. Equal amounts of PA released from 20:80 CPTEG:CPH,
50:50 CPTEG:CPH, 20:80 CPH:SA, and 50:50 CPH:SA
nanoparticles and native PA were adsorbed to Imject Alum
(Fisher Scientific). A/J mice (Jackson Laboratories, Bar Harbor,
Maine) were immunized subcutaneously in the nape of the
neck with a dose of 10 μg of the PArel or native PA (3 or 4 mice
per group). Each mouse was given a second immunization on
day 15 with 10 μg of the PArel or native PA corresponding to
the primary immunization regimen, euthanized on day 21, and
serum collected. All animal procedures were conducted with
the approval of the Iowa State University Institutional Animal
Care and Use Committee.
Enzyme-Linked Immunosorbent Assay (ELISA): PA-
Specific Serum Antibody Response. PA-specific serum
antibody response (total IgG [H + L]) and PArel antigenicity
were analyzed via ELISA using a previously described method
with modifications.19 High-binding 96-well ELISA plates
(Fisher Scientific) were coated in PBS buffer (pH 7.2, 0.05
M) with 0.5 μg/mL native PA or PArel overnight at 4 °C. After
washing with buffer (PBS containing 0.5% Tween 20 (PBS-T)),
plates were blocked for 2 h (PBS containing 0.5% Tween 20
(PBS-T) and 2% gelatin) at room temperature, washed three
times in PBS-T, and incubated with mouse serum (from
individual mice, not pooled) for 24 h at dilutions from 1:1,000
to 1:1,000,000 overnight at 4 °C. The following day, plates
were washed three times in PBS-T, incubated with alkaline
phosphatase-conjugated goat anti- IgG [H + L] antibody
(Jackson ImmunoResearch Laboratories, West Grove, PA) for
2 h at room temperature, washed again, and incubated with
alkaline phosphatase substrate buffer (Sigma Aldrich) for 2 h at
room temperature. Absorbance was measured at an optical
density (OD) of 405 nm using a Spectramax 190 plate reader
(Molecular Devices, Sunnyvale, CA). Each sample was analyzed
in triplicate.
ELISA for Serum Antibody Avidity. Serum antibody
avidity was determined by modifying an ELISA method
described previously.19 The avidity assay was performed
similarly to the serum antibody response protocol described
above. Following serum incubation for 24 h at a dilution of
1:1,000,000, the chaotropic agent, sodium thiocyanate, was
added to the wells using incremental increases over a
concentration range from 0 to 5 M. Plates were incubated for
20 min at room temperature and then washed four times in
PBS-T. The detection of bound serum antibody was performed
as described above. Relative avidity index is defined as the
concentration of sodium thiocyanate required to decrease the
optical density by 50% of that obtained for each control well
(i.e., no sodium thiocyanate). Antibody titers were too low to
measure the avidity of the antibody response for serum samples
obtained from mice immunized with PA released from the
CPH:SA nanoparticles.
Lethal Toxin in Vitro Cytotoxicity Assay. The lethal
toxin in vitro cytotoxicity assay was modified from a previously
described method.6 The murine macrophage-like cell line RAW
264.7 obtained from ATCC (Manassas, VA) was maintained in
culture at 37 °C in a 5% CO2 humidity using high glucose
DMEM medium (Invitrogen, Carlsbad, CA) supplemented
with 10% heat-inactivated FBS (Valley Biomedical, Winchester,
VA), 100 IU/mL penicillin, and 10 μg/mL streptomycin
(Mediatech, Herndon, VA). For the lethal toxin in vitro
cytotoxicity assay, RAW cells were transferred to a 96-well plate
(100,000 cells per well) grown to approximately 90%
confluency in 100 μL of medium over two days. Approximately
12 μL of each treatment (PArel, PA-loaded nanoparticles, blank
nanoparticle controls, medium only control (negative control
and 100% cell survival), native PA (positive control and 100%
cell death), LF (NIH Biodefense and Emerging Infections
Research Resources Repository, Manassas, VA) control, and
cell lysis buffer) diluted in RAW medium was added to the cells
with 0.3 μg/mL LF for no more than 6 h. The amount of PA
released from the nanoparticles was calculated from the release
curve in Figure 1. This assay was also utilized to investigate
antibody neutralization and shelf life (i.e., PA stability) of the
PA-loaded nanoparticles. For antibody neutralization assess-
ment, individual serum samples (dilutions ranging from 1:100
to 1:204800) from the different immunized mouse groups
(described in the in vitro release of PA for in vivo administration
of the PArel section) were added to the cells along with native
PA (0.8 μg/mL) and LF (0.3 μg/mL). For antibody
neutralization assessment, the positive control was medium
only (100% cell survival), and the negative control was native
PA (100% cell death). Samples were then allowed to incubate
for up to 6 h, after which the CellTiter 96 Non-Radioactive Cell
Proliferation Assay (MTT) (Promega, Madison, WI) was used
to determine cell viability. Optical density (OD) was measured
at 570 nm with a background (690 nm) subtraction as
recommended by the manufacturer’s protocol. Antibody
neutralization was considered significant when measured OD
Figure 1. PA was released from polyanhydride nanoparticles in a
chemistry dependent manner. (A) Release of PA from polyanhydride
nanoparticles over 60 days and (B) the change in pH of PBS buffer
(pH 7.6, 0.1 M) from nanoparticle degradation over 30 days. Error
bars represent standard deviation of three replicates performed in
three independent experiments.
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values fell below 50% of the positive control OD value. Data are
presented as % residual activity, as determined by eq 1:
=
−
−
×% residual activity
OD OD
OD OD
100
sample neg control
pos control neg control (1)
Thermal Stability of Stored Dry Powder PA-Loaded
Nanoparticle Formulations. Bioactivity was tested with the
lethal toxin in vitro cytotoxicity assay6 to determine the ability
of each formulation to preserve and release active PA. The
thermal stability upon storage was studied in formulations that
included PA loaded into the nanoparticles (dry) (labeled by
polymer chemistry), PA dissolved in PBS buffer (labeled
“PBS”), or PA absorbed to alum (labeled “Alum”). All
formulations were stored under desiccant at four different
temperatures, 40, 25, 4, and −20 °C, for four months.
Following storage, the formulations were tested at prescribed
times for their ability to preserve PA activity using the lethal
toxin in vitro cytotoxicity assay as described previously.6 PA-
loaded nanoparticle bioactivity was evaluated at a concentration
of 125 μg/mL for 6 h. This nanoparticle dose was chosen
because after 6 h of release (assay incubation time) the
resultant PA concentration was the same as that administered
in the positive control (i.e., 0.8 μg/mL native PA). It is
important to note that nanoparticle formulations investigated in
this study were stored dry and were not added to aqueous
buffers or medium until initiation of the cytotoxicity study,
which lasted for 6 h. This is in contrast to the PA controls (i.e.,
PBS and Alum), which were stored in solution to mimic the
current storage strategy of the AVA vaccine. The nanoparticle
storage conditions in this study are distinctly different from
those in the studies investigating PA release, activity, structure,
antigenicity, and immunogenicity (Figures 1−4) in which the
nanoparticles were incubated in an aqueous environment for
extended time periods (see previous methods) to enable
sufficient release of the encapsulated protein.
Statistical Analysis. Statistical analyses performed using
JMP 7 (Cary, NC) and comparisons between treatments were
made with Tukey’s HSD (honestly significant difference) to
determine statistical significance and p-values ≤0.05 were
considered significant.
■ RESULTS
Polymer and Nanoparticle Characterization. Consis-
tent with previous work, polymer characterization by 1H NMR
indicated that the polymer molecular weights were within the
desired ranges of 9,000−15,000 Da.31,33,34 The structure and
composition of the polymers were also confirmed using NMR.
SEM images (data not shown) indicated that protein-loaded
and blank nanoparticles resulted in similar size (212 ± 43 nm)
and morphology as previously reported.16,19,27,29,35 Particle
yield was approximately 80% (recovery after filtration).
In Vitro PA Release and pH of Nanoparticle
Degradation Were Dictated by Chemistry. Release of
PA and change in pH due to nanoparticle degradation were
evaluated as a function of time. As shown in Figure 1, polymer
chemistry-dependent protein release kinetics and buffer
acidification were observed. Increasing the content of SA or
CPTEG relative to the CPH content resulted in a more rapid
release of encapsulated PA (Figure 1A). The 20:80
CPTEG:CPH particles provided the slowest PA release profile.
This is consistent with previously published studies demon-
strating chemistry-dependent release profiles of other proteins
Figure 2. 50:50 CPTEG:CPH best preserved the structural integrity of
PA while CPH:SA nanoparticle chemistries cause a loss in secondary
and tertiary structural integrity. (A) Secondary structure as measured
by circular dichroism (CD) and (B) tertiary structure as measured by
fluorescence spectroscopy after two days of release from polyanhy-
dride nanoparticles.
Figure 3. CPTEG:CPH nanoparticle chemistries released biologically
active and antigenic PA. (A) Residual antigenicity and (B) residual
activity of PA after two days of release from polyanhydride
nanoparticles. The direct ELISA was performed with 0.5 μg/mL
PArel from the nanoparticles. The biological assay was performed by
incubating 6.4 μg/mL PArel from polyanhydride nanoparticles with 0.3
μg/mL LF with RAW cells for 6 h. Error bars represent standard
deviation of 3 replicates. Treatments with different letters are
significantly different from one another at p < 0.05.
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from polyanhydride nanoparticles.22−25,27,28,30,36 The effect of
the polymer chemistry is also reflected in the pH profile of the
degrading nanoparticles, as shown in Figure 1B. The acidic
monomers produced from the degradation of CPH:SA
nanoparticles have been shown to be water-soluble25 and
result in a greater decrease in pH (ΔpH = 2.5) as compared to
that of the CPTEG:CPH monomers (ΔpH = 0.6). In these
experiments, an even greater pH decrease (ΔpH = 5.0) was
observed upon degradation of poly(lactic-co-glycolic acid)
(PLGA) nanoparticles (data not shown).
Protein Activity and Structural Stability Were
Preserved by Amphiphilic CPTEG:CPH Nanoparticles.
To evaluate PA stability upon release from nanoparticles, a
detailed structural evaluation of the PArel was performed
(Figure 2). In this study, we analyzed the structural integrity of
the PArel that accumulated over 48 h. During this time, the
protein was continually exposed to the acidic microenviron-
ments caused by the degradation of the polymers in an aqueous
environment. The CD spectrum for native PA revealed a
minimum at approximately 208−210 nm and a shoulder at
215−217 nm (Figure 2A). These findings were consistent with
the known CD spectra reported previously for the secondary
structure of PA, and indicate that PA consists mainly of a
mixture of α-helices and β-sheets.6,37 Only the PA exposed to
NFC or released from 50:50 CPTEG:CPH nanoparticle
formulations maintained the native secondary structure (Figure
2A). PA released from all other formulations (20:80
CPTEG:CPH, 20:80 CPH:SA, and 50:50 CPH:SA) resulted
in a significant increase in molar ellipticity (Δε), indicating a
loss of secondary structure.
Tertiary structure analysis, performed with fluorescence
spectroscopy, revealed a red shift in peak position for the PA
released from all the nanoparticle formulations (Figure 2B).
This peak shift indicates exposure to a more polar environment
indicative of protein unfolding.6 However, PA peak intensity
was best preserved by encapsulation into and release from the
amphiphilic 50:50 CPTEG:CPH nanoparticles and to a lesser
extent by encapsulation into and release from 20:80
CPTEG:CPH nanoparticles. The nanoparticle fabrication
conditions appeared to have no detrimental effects on the
tertiary structure of PA. In contrast, the encapsulation of PA
into and release from CPH:SA formulations resulted in a loss of
tertiary structure.
Following the structural evaluation, the relative antigenicity
and bioactivity were assessed for the PArel. The results of this
study, which were used to identify lead candidate formulations
for stabilizing PA, are summarized in Figure 3. PA released
from amphiphilic 50:50 CPTEG:CPH nanoparticles retained
almost 80% of its antigenicity (Figure 3A) and functional
activity (Figure 3B). PA released from 20:80 CPTEG:CPH
nanoparticles retained 52% of its activity but only 20% of its
antigenicity, while CPH:SA-containing nanoparticles preserved
very little PA activity and antigenicity. Nanoparticle fabrication
conditions had little or no detrimental effect on the antigenicity
or activity of PA (Figure 3).
In Vivo Immunization with the PA Released from
Amphiphilic CPTEG:CPH Nanoparticles Resulted in High
Titer, High Avidity, Neutralizing Antibody. Upon
completion of the structural, antigenicity and bioactivity
studies, it was hypothesized that the amphiphilic CPTEG:CPH
nanoparticles would be the most viable candidates for
preserving the PArel, thus enabling a primed PA-specific
antibody response when administered in vivo. In order to
determine the immunogenicity of the released protein, separate
groups of mice were immunized with alum adjuvanted PArel
from the four nanoparticle formulations. We hypothesized that
if PA was degraded upon release from a particular nanoparticle
formulation, as seen for the PA released from the CPH:SA
nanoparticle chemistries (Figures 2 and 3), there would be a
loss in the immunogenicity of the PA. Antibody responses
induced by the released protein were characterized in terms of
titer (Figure 4A), relative avidity (Figure 4B), and neutralizing
antibody titer (Figure 4C). The data indicated that the PA
released from CPH:SA nanoparticles induced a weak humoral
response, while the PA released from the CPTEG:CPH
nanoparticles or PA exposed to the nanoparticle fabrication
conditions resulted in the induction of high titer and avid
antibody responses that were statistically similar to those
induced by native PA. Overall, these data indicate that the
immunogenicity of PA released from the amphiphilic
Figure 4. Mice immunized with PA released from 50:50 and 20:80
CPTEG:CPH, adjuvanted with alum, developed the highest antibody
titers, the most avid antibody response, and highest neutralizing
antibody titers. (A) Antibody titers, (B) antibody avidity (ND (not
determined) for 20:80 and 50:50 CPH:SA because antibody titers
were too low), and (C) antibody neutralization titers of serum samples
from immunized mice. Data is presented as the mean ± SEM of three
replicates. All serum samples were evaluated individually. Treatments
with different letters are significantly different from one another at p <
0.0001.
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CPTEG:CPH nanoparticles was better preserved than that of
PA released from CPH:SA nanoparticles, as evidenced by the 4
log10 difference in antibody titer.
Shelf Life Stability of PA Encapsulated into 50:50
CPTEG:CPH, 20:80 CPTEG:CPH, and 20:80 CPH:SA Was
Superior to That of PA Conjugated to Alum. The ability of
a PA-based vaccine to retain full immunogenicity upon storage
is a major concern. As a measure of PA stability, an in vitro
cytotoxicity assay was employed to assess the preservation of
the biological activity of PA upon storage and immediate
release from polyanhydride nanoparticles. This study was also
an assessment of the thermal stability of the nanoparticles at
various temperatures. During optimization of the cytotoxicity
assay, we determined that coincubating 125 μg/mL of 0.8% PA-
loaded nanoparticles for 6 h with RAW 264.7 cells resulted in a
concentration of PArel that was equivalent to that of the positive
control (i.e., 0.8 μg/mL native PA). Because there was no
statistical difference in the amount of PA released between the
different nanoparticle chemistries in the first 6 h (Figure 1),
direct comparisons between the various polyanhydride
formulations can be made. In this study, the shelf life storage
capabilities of (i) PA loaded into polyanhydride nanoparticles
(dry), (ii) PA in PBS buffer (pH 7.6), or (iii) PA adsorbed to
alum were investigated at multiple time points following
storage at 40, 25, 4, and −20 °C. It is known that adjuvant
solutions containing alum have acidic bulk conditions (pH =
5.6),38 so a PBS buffer group was included to investigate the
effect of storage temperature at a neutral pH on the bioactivity
of PA.
In order to assess the preservation of the biological activity
after dry storage for the desired amount of time (1, 7, 14, 30,
60, and 120 days; only long-term data are presented in this
manuscript), PA-loaded nanoparticles were directly applied to
cultures of RAW 264.7 cells at the initiation of a lethal toxin
cytotoxicity assay. By employing these assay conditions, any of
the PArel was immediately available to bind to the host cell
receptor, thus avoiding any detrimental effects of accumulated
acidic degradation products on the PArel. This is an important
difference between these studies and the stability studies
described in Figures 2−4 in which the PArel was accumulated
over several days in an aqueous environment before assessing
structural and antigenic integrity, and biological activity. After
one week of storage at 40 °C, the biological activity of PA
adsorbed to alum and PA stored in PBS buffer was
undetectable (Supplementary Figures 2A and 2B in the
Supporting Information). Following two weeks and four
months of storage at 25 °C, PA adsorbed to alum and PBS
retained only half of its original bioactivity respectively. After
one month at 25 °C, PA absorbed to alum lost all of its
bioactivity (Supplementary Figure 2A in the Supporting
Information). After two months of storage at 40 °C, PA
encapsulated into 20:80 and 50:50 CPTEG:CPH or 20:80
CPH:SA nanoparticles retained from 60 to 90% of its biological
activity (Supplementary Figure 1 in the Supporting Informa-
tion). After four months of storage, PA encapsulated into 20:80
CPTEG:CPH and CPH:SA retained a significant portion of its
bioactivity (Figure 5). PA adsorbed to alum lost all its
bioactivity after two months of storage at all temperatures
except −20 °C (Supplementary Figure 1 and Supplementary
Figure 2A in the Supporting Information). When stored as a
dry powder, 20:80 CPH:SA nanoparticles were capable of
preserving nearly 100% of the bioactivity of PA at all
temperatures studied for 4 months. In contrast, dry storage
of 50:50 CPH:SA nanoparticles was ineffective at stabilizing PA
under most of the storage conditions tested. It is important to
note that all nanoparticle chemistries were successful in
preserving PA bioactivity when stored at −20 °C and could
be viable vaccine carriers when cold storage is available.
■ DISCUSSION
Next-generation anthrax vaccines need to possess several
attributes, including storage stability and improved immunoge-
nicity to reduce the need for multiple booster injections. In this
work, we have demonstrated that polyanhydride nanoparticle-
based delivery systems can stabilize PA and enhance the shelf
life of PA-based vaccines. In particular, these studies have
shown that amphiphilic polyanhydride nanoparticles provide
controlled antigen release over several weeks, the release of
immunogenic protein capable of inducing high titer, neutraliz-
ing antibody, and extended shelf life storage at tropical and/or
desert temperatures (e.g., 40 °C).
Long-term or repeated antigen exposure (depot effect) is
essential for the development of immunological memory, which
is a part of the rationale for the current immunization regimen
for the AVA vaccine (i.e., five immunizations with yearly
boosters).3 In the event of a bioterrorism attack, this protracted
vaccination strategy may not be viable for treating a naive
Figure 5. Dry powder formulations of PA-loaded 20:80 CPTEG:CPH and CPH:SA polyanhydride nanoparticles were capable of preserving the
activity of PA for four months when stored at 40, 25, 4, and −20 °C. The biological assay was performed by incubating 125 μg/mL nanoparticles
with 0.3 μg/mL LF with RAW cells for 6 h. Error bars represent standard deviation of 3 replicates. Treatments with different letters are significantly
different from one another at p < 0.05.
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population. A need therefore exists for a vaccine capable of
inducing levels of neutralizing anti-PA antibody similar to that
induced by the current immunization regimen, but in a single
dose, that will also improve patient compliance. The nano-
particle-based delivery system described in this work demon-
strated sustained release kinetics for over two months, dictated
by polymer chemistry (Figure 1A), thereby offering an
improved method for delivery of biowarfare vaccines.
Although controlled release kinetics enable long-term antigen
exposure, it is also essential that the antigen remain stable
during fabrication and long-term storage to maintain its
immunogenicity. Alum, an adjuvant that is currently approved
for human use in the U.S., is known to produce an acidic bulk-
environment that can be detrimental for pH-sensitive
proteins.38 While the adsorbed antigen would experience a
less acidic microenvironment on the surface of alum,38 many
pH-sensitive protein immunogens in the bulk would be
denatured and rendered ineffective by the acidic conditions
(pH ∼5.6). PA is a highly labile protein that is sensitive not
only to acidic environments but also to increased temperature:
an effect that is exacerbated as the conditions become more
acidic.6 In this work, we demonstrated the superior PA
stabilization capabilities of a nanoparticle-based delivery system
that preserved the biological activity of PA during fabrication,
delivery, and storage/thermal stability, thereby overcoming
several of the problems associated with the use of alum-based
vaccines.
Because of the absence of water in the process, nanoparticle
fabrication conditions (solvent exposure, sonication, and
vacuum drying) had no detectable effect on the structure,
antigenicity, or activity of PA. This demonstrates the utility of
the polyanhydride nanoparticle fabrication process for labile
proteins, including PA, and is in agreement with similar results
for other proteins exposed to these conditions.29 However, low
pH and elevated temperature have been reported to have more
detrimental impact on the structural stability and bioactivity of
PA.5−7,37,39 As shown in Figure 1B, the pH, due to
CPTEG:CPH nanoparticle erosion, only decreased to approx-
imately 7.0 and was maintained at that value for over 30 days.
In contrast, the erosion of CPH:SA nanoparticles decreased the
pH to 5.2, which was similar to pH changes caused by alum.
The acidic microenvironment caused by degradation of the
CPH:SA nanoparticles correlated with the losses in structure
(Figure 2), antigenicity and bioactivity (Figure 3) of PA
released from these nanoparticles. The PA released from
CPH:SA nanoparticle formulations also failed to prime an
immune response capable of producing high titer, neutralizing
serum antibody (Figure 4). Detailed structural analysis
demonstrated that significant alterations in the secondary and
tertiary structure of the PArel (Figure 2) were important
determinants associated with the loss in immunogenicity,
bioactivity, and quality (i.e., avidity) of the antibody response
(Figure 4). Consistent with these results, it has been reported
that thermally induced ellipticity changes in PA occur in acidic
environments.5−7,39 In addition, at low pH and high temper-
ature conditions, PA is structurally modified to a molten
globular state.6 As observed in this work, this loss of structural
integrity rendered PA biologically inactive and poorly
immunogenic.
Amphiphilic CPTEG:CPH nanoparticles, specifically 50:50
CPTEG:CPH, provided an effective stabilizing environment for
PA. While nearly 80% of PA antigenicity and activity was
preserved upon release from 50:50 CPTEG:CPH nanoparticles
(Figure 3), less antigenicity and activity were preserved (20%
and 50%, respectively) upon release from 20:80 CPTEG:CPH
nanoparticles (Figure 3). From the detailed structural analysis,
it is likely that the alterations in the secondary and tertiary
structure of PA released from the 20:80 and 50:50
CPTEG:CPH nanoparticles (Figure 2) may be responsible
for the loss in antigenicity and bioactivity (Figure 3). These
alterations may result from the slight decrease in pH at 37 °C,
consistent with what was reported by Jiang et al.,6 which
occurred as the acidic degradation products built up over the
duration of the in vitro stability study. However, these
polyanhydride chemistries did not prove to be detrimental to
the immunogenicity of PA. The total and neutralizing antibody
titers as well as the antibody avidity for mice immunized with
PA released from 20:80 or 50:50 CPTEG:CPH nanoparticles
were statistically indistinguishable from those induced by native
PA (Figure 4). Thus, even in such “worst case” conditions (i.e.,
buildup of an acidic microenvironment in a microcentrifuge
tube), the amphiphilic polyanhydride chemistries were not
deleterious to PA.
One of the most difficult challenges to overcome in vaccine
design and development is long-term storage and maintenance
of bioactivity. This is an immediate concern in developing
countries with limited infrastructure for cold storage. In this
work, we tested the thermal stability of PA-loaded nano-
particles, PA adsorbed to alum, and PA in PBS for four months
over a 60-degree temperature range (−20 to 40 °C) while
under dry storage. The changes observed in PA stored with
alum are hypothesized to be a result of the acidic pH
environment combined with the storage temperature. In
contrast, PA stored in PBS buffer at a neutral pH is only likely
to be affected by storage temperature. After two months of dry
storage, all polyanhydride chemistries, except for 50:50
CPH:SA, outperformed the alum group in preserving the
stability of PA at 40, 25, and 4 °C (Supplementary Figure 1 in
the Supporting Information). After four months of dry storage,
PA released from 20:80 CPTEG:CPH and CPH:SA nano-
particles retained its bioactivity (Figure 5). In these studies, it is
important to note that dry formulations were evaluated while
the studies described in Figures 2−4 tested PA-loaded
nanoparticles that were incubated in an aqueous environment
(to obtain the PArel). The dry storage conditions largely
eliminate the buildup of acidic degradation products. This may
explain why the 20:80 CPH:SA nanoparticles preserved PA
bioactivity under these conditions.
Furthermore, these results indicate that the thermal proper-
ties of the copolymers, mainly the glass transition temperature
(Tg), may play an integral role in particle shelf life over
prolonged periods at elevated temperatures. Nanoparticles with
Tgs close to or lower than the storage temperature may lose
their particle structure due to their transition to a rubbery
phase. The Tg values of 20:80 CPTEG:CPH, 50:50
CPTEG:CPH, 20:80 CPH:SA, and 50:50 CPH:SA have been
reported to be 18, 8, 50, and 11 °C, respectively.31,40,41 This
may explain why the polymers with the two lowest Tgs (i.e.,
50:50 CPTEG:CPH and 50:50 CPH:SA) are unable to release
bioactive PA upon extended storage at 25 or 40 °C. In addition,
the hydrophobic 50:50 CPH:SA chemistry may induce
noncovalent hydrophobic interactions with PA that may lead
to aggregation and loss of bioactivity. The 20:80 CPTEG:CPH
and 20:80 CPH:SA nanoparticles revealed similar abilities to
preserve PA at 40 and 25 °C for 4 months, demonstrating
enhanced nanoparticle thermal stability and subsequent protein
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stabilization similar to lyophilized PA stored with stabilizers
after only one month.6 While protein released from the 20:80
CPH:SA nanoparticles was not able to induce a robust antibody
response following immunization, these formulations provided
a suitable dry storage formulation at elevated temperatures. In
contrast, the amphiphilic 20:80 CPTEG:CPH nanoparticles
were able to induce robust antibody responses following
immunization and provide for the preservation of a labile
protein during long-term storage at tropical temperatures. The
preliminary studies described herein have demonstrated a novel
strategy for the design and development of a next-generation
anthrax vaccine formulation with long-term stable storage
capabilities.
■ CONCLUSIONS
Together, the studies reported herein demonstrate the potential
use of a polyanhydride nanoparticle platform in next-generation
vaccines employing recombinant proteins. These polyanhydride
nanoparticles provide the ability to control PA antigen release,
which would provide an in vivo antigen depot capable of long-
term antigen presentation. Additionally, amphiphilic polyanhy-
dride nanoparticles demonstrated superior thermal shelf life
stability and the ability to withstand “worst case” conditions,
thus making them capable of preserving PA bioactivity upon
fabrication and storage at elevated temperatures. Of the four
formulations tested, the amphiphilic 20:80 CPTEG:CPH
nanoparticles demonstrated the best combination of character-
istics to facilitate the stabilization of labile proteins, such as PA,
making them excellent candidates for next-generation single-
dose anthrax vaccines.
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